Customize your JAMA Network experience by selecting one or more topics from the list below.
The Original Investigation “Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: a Subanalysis of the COMPASS Randomized Clinical Trial,”1 published September 30, 2020, contained an error in the Methods section. The sentence listing “(1) 2.5 mg of rivaroxaban twice daily plus 81 mg of aspirin once per day…and (3) 81 mg of aspirin once per day” should instead have noted 100 mg of aspirin in each of the locations it is mentioned. The same values appear in the headings of Table 1, where 81 mg should again have been 100 mg. This article was corrected online.
Error in Methods and Table. JAMA Cardiol. 2021;6(2):246. doi:10.1001/jamacardio.2020.6442
Artificial Intelligence Resource Center